came less. Subsequently she developed a very marked sensitivity rash, and this treatment was therefore stopped after two weeks. Oral erythromycin was then used, but only for 24 hours because of severe vomiting and diarrhoea. Oral lincomycin, 1.5 g. six hourly, was then given and effected complete remission of the fever; she has remained apyrexial since. After lincomycin therapy had been started complement fixation tests for Coxiella burneti revealed 1 :128 (phase I) and 1:4096 (phase II). Subsequent tests showed a rise of phase I titres to 1:2048. When the diagnosis of rickettsial endocarditis seemed in this way to be established, and two weeks after the institution of lincomycin, tetracycline 2 g. daily was added in the light of published data up to that time. The patient has continued with lincomycin and tetracycline in the same doses up to the time of reporting, and it is interesting to note that at no time has she experienced any diarrhoea or other untoward sideeffects. The cost of this treatment is of course very considerable.
At the end of October 1967 she suffered a left-sided hemiplegia, a few days after developing a mitral systolic murmur, but over the past 14 months she has been making a slow but steady improvement. Vesical Atony SIR,-Mr. T. Moore (7 December, p. 646) raises the question of the ultimate residual urine after bladder capacity reduction operations. This is of particular significance in the treatment of bladder-neck sclerosis.'
In 1946 Mr. Terence Millin demonstrated to me the Marion operation of " capitonnage," liberally translating this as " reefing the bladder mainsail." During the intervening 23 years, 11 cases have been so treated in my service. When biopsy of the vault at the time of operation has shown muscle tissue to be still present the preoperative residual urine has entirely disappeared, but it has seemed probable that recovery would have been complete in such cases without capacity reduction. When complete muscle atrophy of the vault has been demonstrated the residual urine has been diminished postoperatively but has never entirely disappeared. In such cases subtotal cystectomy, removing the atrophic vault, is probably more logical in that it restores a completely muscularized organ. Preoperative cystometrograms have given no useful information in arriving at a decision, so it is probable that very few real indications for the operation will present in a urological lifetime. Chlorpromazine SIR,-Professor W. A. Cramond recommends (23 November, p. 497) chlorpromazine for the treatment of acute confusional states " in doses of 100 mg. intramuscularly immediately, repeated in two to three hours if required for two to three more occasions." Later he states, " Elderly and debilitated patients should be given half the recommended daily dose." I think it should be emphasized that a single intramuscular dose of chlorpromazine of 100 mg. in an elderly or debilitated patient is potentially quite dangerous. There is great potential for postural hypotension with brain softening, myocardial infarction, syncope with trauma, and even irreversible shock and death. Chlorpromazine 100 mg. by injection is about equivalent to 400-500 mg. in a single oral dose in its capacity to produce sedation and hypotension. Thus, not only the total daily dosage, but especially the maximum quantity of doses, must be halved in the elderly and infirm.
Professor Cramond rightly warns about the dangers of habituation and toxicity of barbiturates used to promote sleep. He adds, " Chloral hydrate and glutethemide are better drugs." It is hard to see why, since both in equivalent doses also produce habituation and toxic confusion in patients with organic psychoses.-I am, etc., PAUL S. NEMETZ. (1) Because of the small number of patients in the trial it seems unlikely that statistically significant results could have been obtained. The incidence of the relevant symptoms mentioned is about 20-30% with tetracycline. For Mysteclin to give results of clinical importance it should reduce the symptom incidence to about 10-15%. If the rate with tetracycline were 20% and with Mysteclin 10%, it appears that 195 patients would be needed in each group to have an 80% chance of significance on a twosided test at the 5% level. Yet the total number of patients in the trial is only 111-barely more than one-fourth of the required number.
(2) As I understand it, the manufacturer's claim for Mysteclin that it protects against Candida overgrowth in the gut and the associated symptoms, not that it cures them. Surely, therefore, patients with initial symptoms and initial Candida should be excluded. This would reduce the total number in the trial to 67, and would correspondingly increase the probability of a negative result.
(3) In Table IV (5) Surely 10 days' treatment are too few to assess the value of Mysteclin even in a previously untreated, symptom-free and Candidafree group. In the miscellaneous group under trial they are even more inadequate. None the
